KPF
ONCE

K2 Principal Fund’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

K2 Principal Fund’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-23,260
Closed -$2.51M – 373
2019
Q1 		$2.65M Buy
+23,260
New +$1.71M 0.34% 97

Other funds holding ONCE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

K2 Principal Fund's ONCE Position: Q2 2019 in Review

K2 Principal Fund sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q2 2019, closing a stake of 23,260 shares — an estimated $2.51M sold.

K2 Principal Fund first reported a position in ONCE in Q1 2019 and held it in 1 quarter. The position peaked at $2.65M in Q1 2019. 194 funds tracked by Wall St. Rank hold ONCE as of Q2 2019.

  • K2 Principal Fund reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • K2 Principal Fund sold 23,260 Spark Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $2.51M.
  • K2 Principal Fund first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • K2 Principal Fund's Spark Therapeutics, Inc. Common Stock position peaked at $2.65M in Q1 2019.
  • 194 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q2 2019.

Based on K2 Principal Fund's 13F filing for Q2 2019, filed 14 Aug 2019.